Area of research
Nephrology · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Chronic Kidney Disease and Diabetes, Diabetes Treatment and Management, Dialysis and Renal Disease Management, and Pancreatic function and diabetes.
Inter‐organ crosstalk: The kidney's role in systemic health and disease
Baseline Characteristics of the DISCOVER CKD Prospective Cohort
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Investigating the Regulatory Process, Safety, Efficacy and Product Transparency for Nutraceuticals in the USA, Europe and Australia
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Mesenchymal Stem Cells in the Treatment of Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD) and the AKI-to-CKD Transition
Targeted identification of risk and treatment of diabetic kidney disease
The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial
Effects of air pollution on human health – Mechanistic evidence suggested by in vitro and in vivo modelling
Mesenchymal Stem Cell-Derived Exosomes: Toward Cell-Free Therapeutic Strategies in Chronic Kidney Disease
Faecal Microbiota Transplantation and Chronic Kidney Disease
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort
Alleviating symptoms in patients undergoing long-term hemodialysis: a focus on chronic kidney disease-associated pruritus
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Mesenchymal Stem Cell-Derived Extracellular Vesicles to the Rescue of Renal Injury
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease
How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
Epidemiology and burden of chronic kidney disease-associated pruritus
Metformin Attenuates Renal Fibrosis in a Mouse Model of Adenine-Induced Renal Injury Through Inhibiting TGF-β1 Signaling Pathways
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria
Particulate Matter, an Intrauterine Toxin Affecting Foetal Development and Beyond
Differential Effects of ‘Vaping’ on Lipid and Glucose Profiles and Liver Metabolic Markers in Obese Versus Non-obese Mice
Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice